Competitive Intelligence
Understand who is working on what, how far along they are, and what outcomes they are seeing, for any target or disease area. Synapse aggregates clinical trial data, drug interaction landscapes, and published outcomes into a structured competitive view. Enter a target or disease and get a structured, source-attributed view of the competitive field.
Deliverables
Pipeline map by phase
All clinical trials for the target or indication, organized by development phase and status. Each trial entry includes the sponsor, enrollment numbers, primary endpoints, and current status (recruiting, active, completed). For GLP1R, the map covers 317 trials across Phase 1 through Phase 4, with clear status breakdowns showing where development activity is concentrated.
317 TRIALS: DISTRIBUTION BY PHASE & STATUS
Drug interaction landscape
Every known drug interacting with the target, scored by evidence strength with predicate annotations (agonist, antagonist, substrate, etc.) and linked to supporting literature. For GLP1R, 309 drug interactions were mapped: from the top-scoring exenatide (1.00, 29 papers) through the full competitive set including semaglutide, tirzepatide, and dulaglutide.
PAPERS PER DRUG (TOP 6 BY EVIDENCE SCORE)
Trial highlights and outcomes
Curated trial cards showing the most significant active studies, with NCT IDs, sponsors, enrollment, phase, status, and indication. These highlight where the biggest investments are being made and which sponsors are most active in the space. Cross-referenced with published outcomes where available.
TRIAL STATUS DISTRIBUTION: 317 TRIALS
Define your differentiation strategy based on a clear view of the competitive field. Identify gaps in the pipeline, underserved indications, and opportunities to outperform existing approaches.
GLP1R competitive landscape: pipeline, drugs, and active trials
| Drug | Score | Papers | Predicates |
|---|---|---|---|
| Exenatide | 1.00 | 29 | agonist, substrate |
| Semaglutide | 0.95 | 24 | agonist |
| Tirzepatide | 0.92 | 18 | dual agonist |
| Dulaglutide | 0.90 | 21 | agonist |
| Liraglutide | 0.88 | 26 | agonist |
| Lixisenatide | 0.75 | 12 | agonist |
| Albiglutide | 0.70 | 8 | agonist |
EGFR COMPETITIVE LANDSCAPE: ONCOLOGY
| Drug | Score | Papers | Mechanism |
|---|---|---|---|
| Erlotinib | 0.80 | 101 | inhibitor (TKI) |
| Cetuximab | 0.80 | 73 | mAb antagonist |
| Afatinib | 0.80 | 68 | irreversible TKI |
| Lapatinib | 0.80 | 17 | dual TKI |
| Neratinib | 0.80 | 14 | pan-HER TKI |
| Vandetanib | 0.80 | 14 | multi-kinase TKI |
| Gefitinib | 0.80 | 5 | reversible TKI |
EGFR's 2,293 trials (7.2x GLP1R's 317) reflects oncology's crowded competitive field. All 7 top drugs share the same evidence score (0.80), differentiated by mechanism (reversible vs irreversible TKI, mAb, dual/pan-HER).
Methodology
Aggregate clinical trial registry data
Synapse queries ClinicalTrials.gov and other registries for all trials involving the target or indication. Trial metadata including phase, status, enrollment, sponsor, and primary endpoints is extracted and normalized.
Map drugs by mechanism and phase
Drugs are organized by mechanism of action and development phase. Each drug entry is annotated with its interaction type (agonist, antagonist, allosteric modulator, etc.) and evidence score from ChEMBL, DGIdb, and PharmGKB.
Cross-reference with published literature
Trial outcomes and drug interaction data are cross-referenced with published papers. Each interaction links to its supporting evidence, enabling assessment of both the quantity and quality of the competitive intelligence.
Score drug interactions by evidence
Drug interaction scores integrate data quality, replication count, and source diversity. The scoring distinguishes well-validated interactions (high-scoring, multiple sources) from emerging signals (lower scores, fewer sources).
Identify differentiation opportunities
The platform highlights competitive gaps: underserved indications, mechanisms with thin pipeline coverage, and areas where existing approaches have known limitations. These gaps represent strategic opportunities for differentiation.
Target personas
Competitive intelligence analyst
Build comprehensive competitive landscapes in minutes instead of weeks, with structured data and full source attribution.
Strategy lead
Inform go/no-go decisions and positioning strategy with a clear view of who is doing what, and how far along they are.
Investor relations
Articulate competitive positioning with data-backed intelligence on the pipeline landscape and differentiation opportunities.
Explore more
Ready to see your own data analyzed?
Tell us what you're working on. We can show you what the output would look like.